Trabectedin-related rhabdomyolysis: An uncommon but fatal toxicity

Tumori

Volumn 97, Issue 2, 2011, Pages 252-255

  Stoyianni, Aikaterini ^a   Kapodistrias, Nikolaos ^a   Kampletsas, Eleutherios ^a   Pentheroudakis, George ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Outcome; Rhabdomyolysis; Survival; Trabectedin

Indexed keywords

DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PALONOSETRON; TRABECTEDIN;

ABDOMINAL PAIN; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INFILTRATION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; CREATINE KINASE BLOOD LEVEL; CYSTECTOMY; DISEASE ASSOCIATION; DIURETIC THERAPY; DRUG FATALITY; DRUG TREATMENT FAILURE; FATALITY; FEMALE; HUMAN; HUMAN TISSUE; HYDRATION; HYSTERECTOMY; KIDNEY FAILURE; LEIOMYOSARCOMA; LIVER FUNCTION TEST; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROURETERECTOMY; OUTCOME ASSESSMENT; PHYSIOTHERAPY; POSTOPERATIVE PERIOD; RHABDOMYOLYSIS; SIDE EFFECT; SIGMOIDECTOMY; UTERUS BIOPSY; UTERUS SARCOMA;

EID: 79957661764     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700223     Document Type: Article

References (10)

1. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res, 7: 231-242, 2001. (Pubitemid 32183024)
2. Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A: Phase I and pharmacokinetic study of Yonelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumors. Eur J Cancer, 39: 1842-1851, 2003.
3. McMeekin DS, Lisyanskaya A, Crispens M, Oza AM, Braly P, Doering D, Bayever E, Michiels B, Markman M: Single-agent tabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of amulticenter phase II study. Gyn Oncol, 114: 288-292, 2009.
4. Gronchi A, Le Cesne A, Bui NB, Palmerini E, Demetri G, Hohenberger P, Hohl RJ, Pilotti S, Perez I, Lardelli P: A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced/round cell liposarcoma (MRCL). J Clin Oncol, 27: 15s, 2009.
5. Villalona-Calero MA, Eckhardt SA, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res, 8: 75-85, 2002. (Pubitemid 34101461)
6. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol, 22: 890-899, 2004. (Pubitemid 41103601)
7. Skorupa A, Beldner M, Kraft A, Montero AJ: Fatal rhabdomyolysis as a complication of ET-743 (yondelis) chemotherapy for sarcoma. Cancer Biol Ther, 6: 1015-1017, 2007. (Pubitemid 351574950)
8. Forouzesh B, Hidalgo M, Chu Q, Mita A, Mita M, Schwartz G, Jimeno J, Gómez J, Alfaro V, Lebedinsky C, Zintl P, Rowinsky EK: Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res, 15: 3591-3599, 2009.
9. Gomez J, Lazaro LL, Guzman C, Gonzalez A, Misset J, Twelves C: Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol, 19, 2000.
10. Breumer JH, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O: Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Curr Cl Pharm, 4: 38-42, 2009.